Victory Capital Management
CTMX icon

Victory Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Victory Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.4K Buy
19,306
+4,145
+27% +$15.8K ﹤0.01% 2359
2026
Q1 		$71.3K Buy
15,161
+439
+3% +$2.23K ﹤0.01% 2294
2025
Q4 		$62.7K Buy
14,722
+601
+4% +$2.28K ﹤0.01% 2312
2025
Q3 		$45K Buy
14,121
+1,686
+14% +$3.8K ﹤0.01% 2349
2025
Q2 		$28.2K Buy
+12,435
New +$20K ﹤0.01% 2420
2021
Q4 		– Sell
-3,269,112
Closed -$16.6M – 2790
2021
Q3 		$16.6M Buy
3,269,112
+400,126
+14% +$2.14M 0.02% 954
2021
Q2 		$18.2M Buy
2,868,986
+100,104
+4% +$779K 0.02% 935
2021
Q1 		$21.4M Buy
2,768,882
+451,485
+19% +$3.57M 0.02% 885
2020
Q4 		$15.2M Sell
2,317,397
-110,409
-5% -$789K 0.02% 983
2020
Q3 		$16.1M Buy
2,427,806
+150,846
+7% +$1.12M 0.02% 890
2020
Q2 		$19M Sell
2,276,960
-495,466
-18% -$4.6M 0.03% 805
2020
Q1 		$21.3M Sell
2,772,426
-41,025
-1% -$286K 0.04% 634
2019
Q4 		$23.4M Buy
2,813,451
+191,329
+7% +$1.29M 0.03% 769
2019
Q3 		$19.4M Buy
2,622,122
+636,132
+32% +$6.28M 0.02% 804
2019
Q2 		$22.3M Buy
1,985,990
+330,460
+20% +$3.46M 0.04% 576
2019
Q1 		$17.8M Buy
1,655,530
+735,320
+80% +$10.9M 0.04% 596
2018
Q4 		$13.9M Buy
920,210
+29,810
+3% +$442K 0.03% 640
2018
Q3 		$16.5M Buy
890,400
+773,080
+659% +$17.6M 0.03% 656
2018
Q2 		$2.68M Sell
117,320
-6,710
-5% -$171K 0.01% 1010
2018
Q1 		$3.53M Buy
+124,030
New +$3.54M 0.01% 903

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Victory Capital Management's CTMX Position: Q2 2026 in Review

Victory Capital Management increased its CytomX Therapeutics (CTMX) stake by 27% in Q2 2026, buying an estimated $15.8K and bringing the position to 19,306 shares worth $72.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2359.

Victory Capital Management first reported a position in CTMX in Q1 2018 and has held it in 20 quarters since. The position peaked at $23.4M in Q4 2019. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Victory Capital Management held 19,306 shares of CytomX Therapeutics worth $72.4K as of Q2 2026.
  • Victory Capital Management bought 4,145 CytomX Therapeutics shares in Q2 2026, an estimated $15.8K.
  • CytomX Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2359 holding.
  • Victory Capital Management first reported a position in CytomX Therapeutics in Q1 2018 and has held it in 20 quarters since.
  • Victory Capital Management's CytomX Therapeutics position peaked at $23.4M in Q4 2019.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.